Strategic actions supporting large-scale clinical trials

The purpose of this call for proposals is to support distinct strategic clinical research activities which are part of a large-scale clinical trial that has the potential to achieve rapid advances in the clinical development of new or improved medical interventions against poverty-related infectious diseases within the scope of the EDCTP programme.

CAPRISA-018
A randomised controlled trial to assess the safety, acceptability and pharmacokinetics of a sustained-release tenofovir-alafenamide sub-dermal implant for HIV prevention in women

Centre for the Aids Programme of Research in South Africa (CAPRISA) (South Africa) with partners from Ireland and France
Grant agreement: SRIA-2015-1061
Project coordinator: Prof Salim S. Abdool Karim, CAPRISA, South Africa
Starting date:
1 January 2017
Duration: 60 months
Total project value: EUR 19,814,470
EDCTP grant amount: EUR 9,814,470
Cofunding from: to be confirmed

GREAT
Globally relevant AIDS vaccine Europe-Africa trials partnership

University of Oxford (United Kingdom) with partners from Kenya, The Netherlands, Uganda, United Kingdom, United States, and Zambia
Grant agreement: SRIA-2015-1066
Project Coordinator:
Prof. Tomáš Hanke, University of Oxford, United Kingdom
Starting date:
1 January 2017
Duration: 60 months
Total project value: EUR 16,810,411
EDCTP grant amount:
 EUR 7,092,010
Cofunding from: International AIDS Vaccine Initiative (IAVI Inc., USA); University of Oxford (UK); and Imperial College of Science, Technology and Medicine (University of London, UK)
Grantee press release
Website

Predict-TB
Using biomarkers to predict TB treatment duration

Stellenbosch University (South Africa) with partners from Germany, The Netherlands, South Africa, and the United Kingdom
Grant agreement: SRIA-2015-1065
Project coordinator:
Prof. Gerhard Walzl, Stellenbosch University, South Africa
Starting date:
1 February 2017
Duration: 60 months
Total project value: EUR 25,222,905
EDCTP grant amount: EUR 7,722,491
Cofunding from: Bill & Melinda Gates Foundation (USA); National Institutes of Health (USA); National Institute of Allergy & Infectious Diseases (USA)